Comprehensive Review on Analytical and Bioanalytical Methods for Quantification of Anti-Angiogenetic Agents used in Treatment of Cervical Cancer

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Parikh Nisha, Parmar Srushti, Dave Bhavarth, Mohammad Kaif, Parikh Palak
{"title":"Comprehensive Review on Analytical and Bioanalytical Methods for Quantification of Anti-Angiogenetic Agents used in Treatment of Cervical Cancer","authors":"Parikh Nisha, Parmar Srushti, Dave Bhavarth, Mohammad Kaif, Parikh Palak","doi":"10.2174/0115734129270020231102081109","DOIUrl":null,"url":null,"abstract":"Abstract: Cervical cancer is one of the most prevalent forms of cancer occurring across the world and it has been observed that about 99.7% of cervical cancer cases occur due to infections with the Human papillomavirus (HPV). Over prolonged durations, cervical cancer can lead to complications such as vaginal bleeding, itching, and in more severe instances, even the fatality of the individual. Cervical cancer is an essential cause of death at an early age as it affects young women higher than other populations. The most frequent drugs used in its treatment include antiangiogenic drugs. This review summarizes analytical techniques used for the quantification of anti-angiogenic agentsBevacizumab, Sunitinib, Pazopanib, Brivanib, and Imatinib. Furthermore, an in-depth description of numerous techniques including NIR (1), HPLC (10), LC-MS (28), and HPTLC (1) approaches used to determine and quantify these agents have been provided in this review. Based on the matrix utilized, the following details were discussed: analytical conditions, detection limits, and solvent used in sample preparation. Our review holds significant importance within the scientific community, offering valuable insights into commonly employed measurement techniques and the latest advancements in these approaches.","PeriodicalId":10889,"journal":{"name":"Current Pharmaceutical Analysis","volume":"18 6","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmaceutical Analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115734129270020231102081109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Cervical cancer is one of the most prevalent forms of cancer occurring across the world and it has been observed that about 99.7% of cervical cancer cases occur due to infections with the Human papillomavirus (HPV). Over prolonged durations, cervical cancer can lead to complications such as vaginal bleeding, itching, and in more severe instances, even the fatality of the individual. Cervical cancer is an essential cause of death at an early age as it affects young women higher than other populations. The most frequent drugs used in its treatment include antiangiogenic drugs. This review summarizes analytical techniques used for the quantification of anti-angiogenic agentsBevacizumab, Sunitinib, Pazopanib, Brivanib, and Imatinib. Furthermore, an in-depth description of numerous techniques including NIR (1), HPLC (10), LC-MS (28), and HPTLC (1) approaches used to determine and quantify these agents have been provided in this review. Based on the matrix utilized, the following details were discussed: analytical conditions, detection limits, and solvent used in sample preparation. Our review holds significant importance within the scientific community, offering valuable insights into commonly employed measurement techniques and the latest advancements in these approaches.
宫颈癌治疗中抗血管生成药物定量分析和生物分析方法综述
摘要:宫颈癌是世界上最常见的癌症之一,据观察,约99.7%的宫颈癌病例是由人乳头瘤病毒(HPV)感染引起的。如果持续时间长,宫颈癌会导致阴道出血、瘙痒等并发症,在更严重的情况下,甚至会导致患者死亡。宫颈癌是早期死亡的主要原因,因为它对年轻妇女的影响高于其他人群。最常用的治疗药物包括抗血管生成药物。本文综述了用于定量抗血管生成药物贝伐单抗、舒尼替尼、帕唑帕尼、布里瓦尼和伊马替尼的分析技术。此外,本综述还深入描述了用于确定和量化这些药物的许多技术,包括近红外光谱(1)、高效液相色谱(10)、LC-MS(28)和HPTLC(1)方法。根据所使用的基质,讨论了以下细节:分析条件,检出限和样品制备中使用的溶剂。我们的综述在科学界具有重要意义,为常用的测量技术和这些方法的最新进展提供了有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
85
审稿时长
3 months
期刊介绍: Aims & Scope Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信